MSN: Artelo Biosciences moves into glaucoma research with fully funded clinical study
Research shows that petrolatum-based eye ointments can cause the device to swell and potentially rupture, prompting an urgent update to clinical guidance Widely-used eye ointments can cause glaucoma ...
SAN DIEGO--(BUSINESS WIRE)--MediPrint® Ophthalmics, a clinical-stage ophthalmic drug delivery company, continues to advance its innovative glaucoma program following the successful completion of its ...
Business Wire: ViaLase and the John A. Moran Eye Center Announce Research Partnership to Accelerate Glaucoma Research and Innovation
ALISO VIEJO, Calif.--(BUSINESS WIRE)--ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced a ...
ViaLase and the John A. Moran Eye Center Announce Research Partnership to Accelerate Glaucoma Research and Innovation
Healio: ‘No clinical basis’: Doctors may be using outdated glaucoma rule of thumb
Please provide your email address to receive an email when new articles are posted on . The odds of glaucoma treatment were greater with IOP above 22 mm Hg. Current research shows a ‘continuous’ link ...
‘No clinical basis’: Doctors may be using outdated glaucoma rule of thumb
Business Insider: Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients
Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmology First patient enrollment anticipated in Q2 2026 SOLANA BEACH, Calif ...
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients
Healio: Clinical use of both OCT, OCT angiography may help assess risk for glaucoma progression
Clinical use of both OCT, OCT angiography may help assess risk for glaucoma progression